{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:55:51Z","timestamp":1758992151933},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T00:00:00Z","timestamp":1106611200000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Evaluation of extended treatment interruption (TI) in chronic HIV infection among patients successfully treated with antiretroviral therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An observational analysis of 25 patients in a prospectively followed cohort with chronic HIV infection, viral loads &lt;500 HIV\u20101 RNA copies\/mL for at least 6 months, and an interruption in therapy of \u226528 days duration was carried out. Follow up was divided into 3\u2010month time periods for analysis. The effects of time period, stratification group and stratification group by time period interactions on CD4 counts were tested using a mixed model. Univariate comparisons among patient characteristics and responses were performed using Fisher's exact test or the Wilcoxon rank sum test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At initiation of TI, the median CD4 count was 799 cells\/\u03bcL. TI duration was a median of 7.1 months. HIV RNA rebounded to a median maximum level of 75 000 copies\/mL. Maximum viral rebound was significantly greater in patients who were male, had lipodystrophy and had zenith HIV RNA prior to TI of \u226550 000 copies\/mL. Lower CD4 cell counts were observed during TI in patients with lipodystrophy, zenith HIV RNA \u226550 000 copies\/mL, history of AIDS, HIV infection \u22655 years and presuppression CD4 count \u2264350 cells\/\u03bcL. Patients who reinitiated therapy had shorter TI duration, presuppression CD4 count \u2264350 cells\/\u03bcL, previous AIDS diagnosis and lipodystrophy. No patients developed adverse or AIDS\u2010defining events during TI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long\u2010term TI resulted in greater immune deterioration in patients with high viral set points or low CD4 cell counts prior to initiation of suppressive antiretroviral therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2005.00257.x","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T14:02:28Z","timestamp":1106661748000},"page":"7-12","source":"Crossref","is-referenced-by-count":13,"title":["Extended antiretroviral treatment interruption in HIV\u2010infected patients with long\u2010term suppression of plasma HIV RNA"],"prefix":"10.1111","volume":"6","author":[{"given":"CJ","family":"Achenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Till","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FJ","family":"Palella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MD","family":"Knoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SM","family":"Terp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AU","family":"Kalnins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RL","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,1,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00001"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00002"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)03515-1"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200012220-00007"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102153440702"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.14.6410-6417.2001"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200207260-00013"},{"key":"e_1_2_6_10_2","first-page":"1198","article-title":"Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus\u2010infected patients","volume":"186","author":"Tebas P","year":"2002","journal-title":"implications for intermittent therapeutic strategies"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922202760265588"},{"key":"e_1_2_6_12_2","first-page":"126","article-title":"Immunological changes during treatment interruption","volume":"17","author":"Poulton MB","year":"2003","journal-title":"risk factors and clinical sequelae"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007070-00008"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/315339"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-12-199706150-00003"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109280-00030"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009080-00008"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200303070-00022"},{"key":"e_1_2_6_19_2","first-page":"1","article-title":"Guidelines for using antiretroviral agents among HIV\u2010infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV","volume":"51","author":"Panel on Clinical Practices for the Treatment of HIV.","year":"2002","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_6_20_2","first-page":"1","article-title":"British HIV Association (BHIVA) guidelines for the treatment of HIV\u2010infected adults with antiretroviral therapy","volume":"1","author":"Pozniak A","year":"2003","journal-title":"HIV Med Suppl"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00257.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00257.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:06:57Z","timestamp":1696950417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00257.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00257.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00257.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}